View More View Less
  • 1 Dél-pesti Centrumkórház, Országos Hematológiai és Infektológiai Intézet, Hematológiai és Őssejt-Transzplantációs Osztály, Budapest, Albert Flórián út 5–7.
  • | 2 Dél-pesti Centrumkórház, Országos Hematológiai és Infektológiai Intézet, Molekuláris Genetikai Laboratórium, Budapest
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $96.00

Összefoglaló. A monoklonális ellenanyagokat termelő plazmasejtburjánzás, a myeloma multiplex kezelésére a monoklonális ellenanyag-terápia viszonylag későn lépett a klinikumba. 2020 végén már három törzskönyvezett antitest, az elotuzumab, a daratumumab és az isatuximab áll rendelkezésre különböző gyógyszer-kombinációk részeként a myeloma betegség eltérő terápiás helyzeteinek megoldására. Emellett számos új antitest, nemcsak „csupasz” antitestek, hanem antitestdrug konjugátumok és bispecifikus antitestek állnak viszonylag előrehaladott klinikai fejlesztési stádiumban, közvetlenül a bevezetés előtt. Összefoglalónkban a rendelkezésünkre álló nagyszámú tanulmány eredményeit ismertetjük, fogódzót kínálva a terület eredményeit kritikus szemmel megismerni kívánó olvasóknak.

Summary. Although multiple myeloma is a plasma cell malignancy known to produce monoclonal antibodies, therapeutic monoclonal antibodies entered late into this clinical field. At the end of 2020, we already have three approved monoclonal antibodies: elotuzumab, daratumamab, and isatuximab – available in different drug combinations at different therapeutic settings of multiple myeloma. Additionally, there are a number of new antibodies, not just „bare” antibodies but antibody-dug conjugates and bispecific antibodies stand at advanced stages of clinical development, frequently just before approval. In this review, results of the large number of clinical studies are critically detailed in order to provide assistance for our interested readers.

  • 1

    Pierpoint TM, Limper CB, Richards KL. Past, present, and future of rituximab – The world’s first oncology monoclonal antiboddy therapy. Front Oncol 2018; 8: 163.

  • 2

    Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol 2016; 43: 676–681.

  • 3

    D’Agostino M, Bertamini L, Oliva S, Boccadoro M, Gay F. Pursuing a curative approach in multiple myeloma: A review of new therapeutic strategies. Cancers 2019; 11: 2015.

  • 4

    Nooka AK, Lonial S. Mechanism of action and novel IMID-based compounds and combinations in multiple myeloma. Cancer J 2019; 25: 19–31.

  • 5

    Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol 2015; 6: 368.

  • 6

    Meyer S, Leusen JHW, Boross P. Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. MAbs 2014; 6: 1133–1144.

  • 7

    Gül N, Babes L, Siegmund K, Korthouwer R, Bögels M, et al. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest 2014; 124: 812–823.

  • 8

    Overdijk MB, Jansen JHM, Nederend M, Lammerts van Bueren JJ, Groen RWJ, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor–mediated cross-linking. J Immunol 2016; 197: 807–813.

  • 9

    Oliva S, Troia R, D’Agostino M, Boccadoro M, Gay F. Promises and pitfalls in the use of PD-1/PD-L1 inhibitors in multiple myeloma. Front Immunol 2018; 9: 2749.

  • 10

    D’Agostino M, Gazzera G, Cetani G, Bringhen S, Boccadoro M, Gay F. Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma. Curr Med Chem 2019; 26: 5968–5981.

  • 11

    Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 2016; 128: 384–394.

  • 12

    Bouchard H, Viskov C, Garcia-Echeverria C. Antibody-drug conjugates—A new wave of cancer drugs. Bioorg Med Chem Lett 2014; 24: 5357–5363.

  • 13

    D’Agostino M, Innorcia S, Boccadoro M, Bringhen S. Monoclonal antibodies to treat multiple myeloma: A dream come true. Int J Mol Sci 2020; 21: 8192.

  • 14

    Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. J Hematol Oncol 2015; 8: 130.

  • 15

    Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NBM, Hamid M. ScFv antibody: Principles and clinical application. Clin. Dev. Immunol 2012; 2012: 980250.

  • 16

    Nadeem O, Tai Y-T, Anderson KC. Immunotherapeutic and targeted approaches in multiple myeloma. Immuno Targets Ther 2020; 9: 201–215.

  • 17

    Tai Y-T, Dillon M, Song W, Leiba M, Li X-F, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008, 112, 1329–1337.

  • 18

    Pazina T, James AM, MacFarlane AW, Bezman NA, Henning KA, et al. The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and independent mechanisms. Oncoimmunology 2017; 6: e1339853.

  • 19

    Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, et al. A phase I, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012; 120: 552–559.

  • 20

    Bristol Myers Squibb Reports Primary Results of ELOQUENT-1 Study Evaluating Empliciti (elotuzumab) Plus Revlimid (lenalidomide) and Dexamethasone in Patients with Newly Diagnosed, Untreated Multiple Myeloma https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Reports-Primary-Results-of-ELOQUENT-1-Study-Evaluating-Empliciti-elotuzumab-Plus-Revlimid-lenalidomide-and-Dexamethasone-in-Patients-with-Newly-Diagnosed-Untreated-Multiple-Myeloma/default.aspx

  • 21

    Lonial S, Vij R, Harousseau J-L, Facon T, Moreau P, Mazumder A, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 2012; 30: 1953–1959.

  • 22

    Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 2018; 379: 1811–1822.

  • 23

    Jakubowiak A, Offidani M, Pégourie B, DeLaRubia J, et al. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs. bortezomib/dexamethasone for relapses/refractory MM. Blood 2016; 127: 2833–2840.

  • 24

    Van de Donk NWCJ, Usmani SZ. CD38 antibodies in multiple myeloma: Mechanisms of action and modes of resistance. Front Immunol 2018; 9: 2134.

  • 25

    Lokhorst HM, Plesner T, Laubach JP, Nahi H, et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med 2015; 373: 1207–1219.

  • 26

    Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial. Lancet 2016; 387: 1551–1560.

  • 27

    Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T et el. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016; 375: 754–966.

  • 28

    Spencer A, Lentsch S, Weisel K, Avet-Loiseasu H, Mark T, et al. Daratumumab plus bortezomib and dexamethasone in relapsed or refractory multiple myeloma. Uő: Dated analysis of CASTOR. Haematologica 2018; 103: 2079–2087.

  • 29

    Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ et al. Daratumumab, lenalidomide, and dexamethason for multiple myeloma. N Engl J Med 2016; 375: 1319–1331.

  • 30

    Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLLUX. Haematologica 2018; 103: 2088–2096.

  • 31

    Endell J, Boxhammer R, Steidl S. Synergistic in Vitro Activity of MOR202, a Human CD38 Antibody, in Combination with Pomalidomide. Blood 2014; 124. Abstract #5712 [ASH 2014 65th Annual Meeting].

  • 32

    Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood 2017; 130: 974–981.

  • 33

    Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomized, multicentre, open label, phase 3 study. Lancet 2020; 396: 186–197.

  • 34

    Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 2018; 378: 518–528.

  • 35

    Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomized, open-label, phase 3 trial. Lancet 2020; 395: 132–141.

  • 36

    Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 2019; 380: 2104–2115.

  • 37

    Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomized, open label, phase 3 study. Lancet 2019; 394: 29–38.

  • 38

    Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial. Blood 2020; 136: 936–945.

  • 39

    Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, nin-inferiority, randomised, phase 3 trial. Lancet Haematol 2020; 7: e370–e380.

  • 40

    Chari A, Rodriguez-Otero P, McCarthy H, Suzuki K, Hungria V, et al. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label phase II study. Br J Haematol 2020; https://doi.org/10.1111/bjh.16980.

  • 41

    Martin T, Strickland S, Glenn M, Charpentier E, Guillemin H, et al. Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. Blood Cancer J 2019; 29: 41.

  • 42

    Michael J, Richter J, Vij R, Cole C, Zonder J, et al. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. Leukemia 2020; 34: 3298–3309. .

    • Crossref
    • Export Citation
  • 43

    Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study. Lancet 2019; 394: 2096–2107.

  • 44

    The interim analysis results of the phase III IKEMA trial. Isatuximab + Kd for the treatment of relapsed and refractory multiple myeloma. https://multiplemyelomahub.com/medical-information/the-interim-analysis-results-of-the-phase-iii-ikema-trial-or-isatuximab-kd-for-the-treatment-of-relapsed-and-refractory-multiple-myeloma

  • 45

    Weisel K, Asemissen AM, Besemer B, Haenel M, Blau IW, Goerner M, Ko Y-D, Dürig J, Staib P, Mann C, et al. Depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG-CONCEPT trial. American Society of Clinical Oncology 2020; 38: Abstract #8508 [ASCO 2020 Annual Meeting].

  • 46

    Van Bueren J, Jakobs D, Kaldenhoven N, Roza M, Hiddingh S, et al. Direct In Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79. Blood 2014; 124: Abstract #3474 [ASH 2014 56th Meeting].

  • 47

    Raab MS, Engelhardt M, Blank A, Goldschmidt H, Agis H, Blau IW, Einsele H, Ferstl B, Schub N, Röllig C, et al. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: A first-in-human, multicentre, phase 1–2a trial. Lancet Haematol 2020; 7: e381–e394.

  • 48

    Krishnan AY, Patel KK, Hari P, Jagannath S, Niesvizky R, Silbermann RW, Berg DT, Li Q, Allikmets K, Stockerl-Goldstein K. A phase Ib study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/refractory multiple myeloma (RRMM): Preliminary results. J Clin Oncol 2020; 38: Abstract #8539 [ASCO 2020 Annual Meeting].

  • 49

    Badros A, Hyjek E, Ma N, Lesokhin A, Dogan A, et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. Blood 2017; 130: 1189–1197.

  • 50

    Mateos MV, Orlowski RZ, Ocio EM, Redriguez-Otero P, Reece D, et al. Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: Phase I KEYNOTE-023 study. Br J Haematol 2019; 186: e117–e121.

  • 51

    Mateos M-V, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, et al. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): A randomised, open-label, phase 3 trial. Lancet Haematol 2019; 6: e459–e469.

  • 52

    Usmani SZ, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM, Yimer HA, LeBlanc R, Takezako N, McCroskey RD, et al. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): A randomised, open-label, phase 3 trial. Lancet Haematol 2019; 6: e448–e458.

  • 53

    Bruins WSC, Zweegman S, Mutis T, Van de Donk NWCJ. Targeted therapy with immunoconjugates for multiple myeloma. Front Immunol 2020; 11: 1155.

  • 54

    Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 2020; 34: 985–1005.

  • 55

    Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, et al. Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): A dose escalation and expansion phase 1 trial. Lancet Oncol 2018; 19: 1641–1653.

  • 56

    Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, et al. Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: An update on safety and efficacy from dose expansion phase I study. Blood Cancer J 2019; 9: 37.

  • 57

    Zhao H, Atkinson J, Gulesserian S, Zeng Z, Nater J, et al. Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody–drug conjugates. Cancer Res 2018; 78: 2115–2126.

  • 58

    Farook AV, Esposti SD, Popat R, Thulasi P, Lonial S, et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomited DREAMM-2 study. Ophthalmol Ther 2020; 9(4): 889–911. https://doi.org/10.1007/s40123-020-00280-8.

  • 59

    Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study. Lancet Oncol 2020; 21: 207–221.

  • 60

    Lee HC, Cohen AD, Chari A, Hultcrantz M, Nooka AK, et al. DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment. J Clin Oncol 2020; 38: Abstract #8519 [ASCO 2020 Annual Meeting].

  • 61

    Cohen AD, Trudel S, Lonial S, Libby EN, Lee HC, Besemer B, Facon T, Nooka AK, Callander NS, Chari A. et al. DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics. J Clin Oncol 2020; 38: Abstract #8541 [ASCO 2020 Annual Meeting].

  • 62

    Caraccio C, Krishna S, Phillips DJ, Schürch CM. Bispecific antibodies for multiple myeloma: A review of targets, drugs, clinical trials, and future directions. Front Immunol 2020; 11: 501.

  • 63

    Raje NS, Jakubowiak A, Gasparetto C, Cornell RF, Krupka HI, Navarro D, Forgie AJ, Udata C, Basu C, Chou J, et al. Safety, clinical activity, pharmacokinetics, and pharmacodynamics from a Phase I study of PF-06863135, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). Blood 2019; 134: Abstract #1869 [ASH 2019 Meeting].

  • 64

    Costa LJ, Wong SW, Bermúdez A, de la Rubia J, Mateos MV, et al. Interim results from the first phase I clinical study of the B-cell maturation antigen (BCMA) 2+1 T-cell engager (TCE) cc-93269 in patients (PTS) with relapsed/refractory multiple myeloma (RRMM). HemaSphere 2020; 4: 59. [Abstract #S205, EHA 2020 25th Congress].

  • 65

    Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, Krönke J, Facon T, Salnikov AV, Lesley R, et al. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol 2020; 38: 775–783.